Pan‐cancer analysis shapes the understanding of cancer biology and medicine
Open Access
- 22 March 2025
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 45 (7) , 728-746
Abstract
Advances in multi‐omics datasets and analytical methods have revolutionized cancer research, offering a comprehensive, pan‐cancer perspective. Pan‐cancer studies identify shared mechanisms and unique traits across different cancer types, which are reshaping diagnostic and treatment strategies. However, continued innovation is required to refine these approaches and deepen our understanding of cancer biology and medicine. This review summarized key findings from pan‐cancer research and explored their potential to drive future advancements in oncology.Keywords
Funding Information
- Self‐supporting Program of Guangzhou Laboratory (SRPG22007)
- National Key Research and Development Program of China (2021YFA0910100)
This publication has 143 references indexed in Scilit:
- Pan‐cancer proteogenomic landscape of whole‐genome doubling reveals putative therapeutic targets in various cancer typesClinical and Translational Medicine, 2024
- A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancerCancer Letters, 2024
- Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic reviewAnnals of Oncology, 2023
- 909P A multi-cancer early detection model based on liquid biopsy of multi-omics biomarkers: A proof of concept study (PROMISE study)Annals of Oncology, 2022
- Pan-cancer integrative histology-genomic analysis via multimodal deep learningCancer Cell, 2022
- Pan-cancer proteomic map of 949 human cell linesCancer Cell, 2022
- Patient‐derived renal cell carcinoma organoids for personalized cancer therapyClinical and Translational Medicine, 2022
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNAAnnals of Oncology, 2020
- T‐cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironmentThe Journal of Pathology, 2020
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityCancer Cell, 2019